Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis

Area of Science:

• Neurology
• Immunology
• Clinical Trials

Background:

• Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Progressive forms of MS present significant management challenges.
• Identifying effective and safe treatments for progressive MS is crucial.

Purpose of the Study:

• To evaluate the safety and efficacy of teriflunomide compared to glatiramer acetate in patients with progressive multiple sclerosis.
• To assess the impact of these treatments on disability progression.

Main Methods:

• A retrospective observational study was conducted at a single center.
• Patients with progressive MS treated for at least one year with teriflunomide or glatiramer acetate were included.
• Cox proportional hazards models were used to compare sustained progression of the Expanded Disability Status Scale (EDSS) and worsening of the Timed 25-Foot Walk (T25FW).

Main Results:

• The study included 29 patients in the teriflunomide group and 30 in the glatiramer acetate group.
• Both teriflunomide and glatiramer acetate were well-tolerated with no serious side effects reported.
• No significant differences were observed between the groups in sustained EDSS progression (HR=1.17, p=0.75) or sustained T25FW worsening (HR=0.56, p=0.26) after adjusting for baseline characteristics.

Conclusions:

• Teriflunomide and glatiramer acetate demonstrated comparable safety and efficacy profiles in an advanced progressive multiple sclerosis population.
• Neither treatment showed substantial differences in tolerability, safety, or slowing disability progression over the study period.
• The small sample size limits definitive conclusions, suggesting further research is warranted.